Trimethoprim-sulfamethoxazole in the treatment of malaria, toxoplasmosis, and pediculosis.
The status of trimethoprim-sulfamethoxazole (TMP-SMZ) as a chemotherapeutic agent for malaria, toxoplasmosis, and pediculosis is reviewed. The use of TMP-SMZ may be advocated for the treatment of malaria when concurrent bacterial infections are present or when conventional antimalarial agents are not available. Present evidence suggests that TMP-SMZ is effective in the treatment of toxoplasmosis; however, its role in treatment of this disease requires study. Although TMP-SMZ can eliminate head louse infections, topical insecticidal preparations are the preferred treatment.
D004338:Drug Combinations / Q000627:therapeutic use; D005493:Folic Acid Antagonists; D006801:Humans; D010373:Lice Infestations / Q000188:drug therapy*; D008288:Malaria / Q000188:drug therapy*; D010963:Plasmodium falciparum; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000188:drug therapy*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D005493:Folic Acid Antagonists; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole